Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 60
Summary
- Conditions
- HDT-AHCT
- Hodgkin Lymphoma
- Multiple Myeloma
- Non Hodgkin Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: A single-center, open-label, pilot study of romiplostim for patients undergoing HDT-AHCT.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04478123
- Collaborators
- Amgen
- Investigators
- Principal Investigator: Gerald Soff, MD Memorial Sloan Kettering Cancer Center